These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 7697342)

  • 1. Tumor suppression. Lessons in p16 from phylum Falconium.
    Sheaff RJ; Roberts JM
    Curr Biol; 1995 Jan; 5(1):28-31. PubMed ID: 7697342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p16INK4 mutations and altered expression in human tumors and cell lines.
    Okamoto A; Demetrick DJ; Spillare EA; Hagiwara K; Hussain SP; Bennett WP; Forrester K; Gerwin B; Greenblatt MS; Serrano M
    Cold Spring Harb Symp Quant Biol; 1994; 59():49-57. PubMed ID: 7587103
    [No Abstract]   [Full Text] [Related]  

  • 3. Regulation and function of the cyclin-dependent kinase inhibitor p16CDKN2.
    Peters G; Parry D; Hara E; Hall M; Bates S; Palmero I
    Leukemia; 1997 Apr; 11 Suppl 3():352-5. PubMed ID: 9209387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-clinical studies with tumor suppressor genes.
    Seth P
    Adv Exp Med Biol; 2000; 465():183-92. PubMed ID: 10810626
    [No Abstract]   [Full Text] [Related]  

  • 5. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas.
    Elisei R; Shiohara M; Koeffler HP; Fagin JA
    Cancer; 1998 Nov; 83(10):2185-93. PubMed ID: 9827724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16.
    Lukas J; Parry D; Aagaard L; Mann DJ; Bartkova J; Strauss M; Peters G; Bartek J
    Nature; 1995 Jun; 375(6531):503-6. PubMed ID: 7777060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent progress in molecular mechanisms of leukemogenesis: the cyclin-dependent kinase 4-inhibitor gene in human leukemias.
    Hirai H; Ogawa S; Hangaishi A; Takahashi T; Kurokawa M; Mitani K; Ueda R; Yazaki Y
    Leukemia; 1997 Apr; 11 Suppl 3():358-60. PubMed ID: 9209389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inactivation of cyclin-dependent kinase inhibitor genes and development of human acute leukemias.
    Ragione FD; Iolascon A
    Leuk Lymphoma; 1997 Mar; 25(1-2):23-35. PubMed ID: 9130611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression.
    Piccinin S; Doglioni C; Maestro R; Vukosavljevic T; Gasparotto D; D'Orazi C; Boiocchi M
    Int J Cancer; 1997 Feb; 74(1):26-30. PubMed ID: 9036865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the cyclin-dependent kinase inhibitors in the development of cancer.
    Hirama T; Koeffler HP
    Blood; 1995 Aug; 86(3):841-54. PubMed ID: 7620180
    [No Abstract]   [Full Text] [Related]  

  • 11. Cell-cycle regulators and cancer.
    Kamb A
    Trends Genet; 1995 Apr; 11(4):136-40. PubMed ID: 7732591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of a cell cycle regulator in hereditary and sporadic cancer.
    Kamb A
    Cold Spring Harb Symp Quant Biol; 1994; 59():39-47. PubMed ID: 7587092
    [No Abstract]   [Full Text] [Related]  

  • 13. Lack of germ-line mutations of CDK4, p16(INK4A), and p15(INK4B) in families with glioma.
    Gao L; Liu L; van Meyel D; Cairncross G; Forsyth P; Kimmel D; Jenkins RB; Lassam NJ; Hogg D
    Clin Cancer Res; 1997 Jun; 3(6):977-81. PubMed ID: 9815774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New tumor suppressor may rival p53.
    Marx J
    Science; 1994 Apr; 264(5157):344-5. PubMed ID: 8153613
    [No Abstract]   [Full Text] [Related]  

  • 15. Aberrations of p16Ink4 and retinoblastoma tumour-suppressor genes occur in distinct sub-sets of human cancer cell lines.
    Aagaard L; Lukas J; Bartkova J; Kjerulff AA; Strauss M; Bartek J
    Int J Cancer; 1995 Mar; 61(1):115-20. PubMed ID: 7705923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme.
    Moulton T; Samara G; Chung WY; Yuan L; Desai R; Sisti M; Bruce J; Tycko B
    Am J Pathol; 1995 Mar; 146(3):613-9. PubMed ID: 7887443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations and altered expression of p16INK4 in human cancer.
    Okamoto A; Demetrick DJ; Spillare EA; Hagiwara K; Hussain SP; Bennett WP; Forrester K; Gerwin B; Serrano M; Beach DH
    Proc Natl Acad Sci U S A; 1994 Nov; 91(23):11045-9. PubMed ID: 7972006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas.
    Tsuzuki T; Tsunoda S; Sakaki T; Konishi N; Hiasa Y; Nakamura M
    Cancer; 1996 Jul; 78(2):287-93. PubMed ID: 8674005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural integrity of the cyclin-dependent kinase inhibitor genes, p15, p16 and p18 in myeloid leukaemias.
    Nakamaki T; Kawamata N; Schwaller J; Tobler A; Fey M; Pakkala S; Lee YY; Kim BK; Fukuchi K; Tsuruoka N
    Br J Haematol; 1995 Sep; 91(1):139-49. PubMed ID: 7577621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenovirus-mediated overexpression of p15INK4B inhibits human glioma cell growth, induces replicative senescence, and inhibits telomerase activity similarly to p16INK4A.
    Fuxe J; Akusjärvi G; Goike HM; Roos G; Collins VP; Pettersson RF
    Cell Growth Differ; 2000 Jul; 11(7):373-84. PubMed ID: 10939591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.